What Is KPV? The Anti-Inflammatory Peptide Explained

α-MSH has strong anti-inflammatory effects. Researchers discovered that most of those effects come from its small KPV fragment. In some studies, KPV showed anti-inflammatory activity similar to or even stronger than full-length α-MSH.

Calming Inflammation

KPV helps reduce inflammation by blocking NF-κB, a key “on switch” for inflammation inside cells. This lowers the production of pro-inflammatory cytokines, the signals that drive inflammation.

Entering Gut Cells

KPV has a unique way into cells. It’s carried by PepT1, a transporter that normally absorbs small peptides from digested food.

PepT1 is normally found in the small intestine, but it increases in the colon during inflammatory bowel disease (IBD). That means KPV may reach inflamed gut tissue more easily.

Gut Inflammation

A key 2008 study in Gastroenterology found:

• KPV enters intestinal and immune cells through PepT1.
• Oral KPV reduced colitis in two mouse models.
• Treated mice had lower pro-inflammatory cytokines.

Skin Inflammation

The skin is one of the most important sources of α-MSH outside the pituitary gland. Research shows α-MSH peptides, including KPV, reduce NF-κB activation in keratinocytes, the main cells of the skin’s outer layer. That’s why KPV is being explored for inflammatory skin conditions.

• What is KPV peptide? A tripeptide (lysine-proline-valine) from the hormone α-MSH, studied for its anti-inflammatory effects.
• What is KPV used for? It’s being researched for gut inflammation, such as colitis, and inflammatory skin conditions.
• How does KPV work? It blocks NF-κB, a key inflammation pathway, and enters gut cells through the PepT1 transporter.
• Does KPV affect skin color? KPV comes from α-MSH, which is involved in pigmentation, but KPV is studied mainly for its anti-inflammatory effects.
• Is KPV FDA-approved? No. An FDA advisory committee recommended it for the compounding list in July 2026, but the FDA hasn’t made a final decision.

• KPV is a three-amino-acid peptide from α-MSH.
• It carries most of α-MSH’s anti-inflammatory power.
• It works by blocking NF-κB and enters gut cells via PepT1.
• Research is mostly animal and lab-based, with limited human data.
• An FDA panel recommended it for compounding in 2026, but it’s not FDA-approved.

• PMC – Dalmasso et al. (2008). PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology
• PMC – α-MSH Related Peptides: A New Class of Anti-Inflammatory and Immunomodulating Drugs
• Bentham Science – The Anti-Inflammatory Effect of Alpha-MSH in Skin (2009)
• RAPS – FDA Advisory Committee Backs Two Controversial Peptides (July 2026)
• McDermott Will & Schulte – PCAC Backs Majority of Peptides in Two-Day Public Meeting
• Buchanan Ingersoll & Rooney – FDA Voted Yes on Six Peptides: The Regulatory Road Ahead